Fakülteler / Faculties

Permanent URI for this communityhttps://hdl.handle.net/11727/1395

Browse

Filters

2014 - 20192

Settings

search.filters.applied.f.publicationcategory: search.filters.publicationcategory.Makale - Ulusal Hakemli DergiSubject: search.filters.subject.Hepatitis C

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Comparison of Haematologic Side Effects of Different Pegylated Interferon-α Molecules Combined With Ribavirin
    (2014) Aydin, Mehtap; Aksoz, Elif; Korkut, Oguzhan; Akhan, Sila; https://orcid.org/0000-0003-4044-9366; HLX-0937-2023
    Objective: Treatment of chronic hepatitis C virus (HCV) infection with pegylated interferon (PegIFN) and ribavirin causes haematological side effects such as anemia, neutropenia and trombocytopenia. This study aimed to evaluate and compare the haematological side effects of PegIFN alpha-2a and PegIFN alpha-2b with ribavirin in the treatment of chronic HCV infection. Methods: 103 patients treated with PegIFN alpha-2b plus ribavirin and 70 patients treated with PegIFN alpha-2a plus ribavirin were included in this retrospective study. Patients' haematological parameters in first and third month's visits were compared with pretreatment test results. Results: In all patients, 21.2% had anemia (haemoglobin <10 g/dL), 3.8% had neutropenia (<750/mm(3)) and 6.2% had thrombocytopenia (<75x10(9)/L) at the end of the third month. When compared with initial levels, significant decreases in haemoglobin, neutrophil and thrombocyte counts were observed at first and third months in both groups. There wasn't a significant decrease in thrombocyte counts in the first month between two groups, however, a more significant decrease in thrombocyte counts were observed in patients who received PegIFN alpha-2a plus ribavirin than the patients receiving PegIFN alpha-2b plus ribavirin during the third month. Conclusions: PegIFN alpha-2b seems to have similar haematologic side effects, compared with PegIFN alpha-2a except the effects on the thrombocyte counts during the third month.
  • No Thumbnail Available
    Item
    The Ways to How Patients with Chronic Hepatitis C Find Out Their Disease and Risk Factors
    (2019) Turan Ozden, Hale
    Introduction: Transmission routes and seroprevalence of hepatitis C virus (HCV) may vary between countries and geographic regions. In this study, we planned to investigate patients with chronic hepatitis C admitted to our hospital in order to identify associated risk factors of HCV transmission in our region. Materials and Methods: Eighty-two patients who were admitted to the Infectious Diseases and Clinical Microbiology Outpatient Clink of our hospital between January 2011-December 2014 and who were diagnosed with chronic hepatitis C and/or liver cirrhosis were included into the study. Results: Forty-six (56.1%) of the patients were female and 36 (43.9%) were male patients. Mean age was 60.8 +/- 10.0 (26-81) year. Most common risk factors were surgical intervention (58.5%) and dental treatment (31.7%). Vast majority of the patients found out about their illnesses during routine examinations (81.7%). Conclusion: Early detection of the HCV infection is important in the follow-up and treatment of the disease. This study also emphasized the importance of routine screening in the detection of anti-HCV positivity.